ProteinLogic
ProteinLogic is a biomarker discovery and exploitation company developing a novel diagnostic platform and products addressing unmet medical needs in infection and inflammatory diseases. Their proprietary ImmiPrint® technology detects patterns in soluble immune proteins in blood, enabling early disease diagnosis, response monitoring, and disease progression prediction, with applications in infectious diseases and oncology.
Industries
Nr. of Employees
small (1-50)
ProteinLogic
50/60 Station Road, Cambridge, CB1 2JH
Patents
Products
Blood-based diagnostic test for ruling-out active tuberculosis
A validated blood-based proteomic diagnostic signature developed to rule out active pulmonary tuberculosis in symptomatic individuals.
Prototype rapid point-of-care TB diagnostic device
Prototype device combining a multiplex immunoassay platform with diagnostic protein signatures for rapid (minutes-to-hours) detection or triage of active TB at community healthcare settings.
Blood-based diagnostic test for ruling-out active tuberculosis
A validated blood-based proteomic diagnostic signature developed to rule out active pulmonary tuberculosis in symptomatic individuals.
Prototype rapid point-of-care TB diagnostic device
Prototype device combining a multiplex immunoassay platform with diagnostic protein signatures for rapid (minutes-to-hours) detection or triage of active TB at community healthcare settings.
Services
Discovery of disease-specific protein biomarker panels and derivation of diagnostic signatures from clinical cohorts.
Design and optimisation of multiplex immunoassays and monoclonal antibody-based measurement platforms for parallel protein quantification.
Computational analysis, statistical modelling and machine-learning to process high-throughput proteomic/genomic data and develop diagnostic algorithms.
Support for multi-site clinical sample collection, study execution and performance assessment against clinical benchmarks.
Formation and leadership of multi-partner consortia and management of externally funded projects (EU, national agency, philanthropic).
Discovery of disease-specific protein biomarker panels and derivation of diagnostic signatures from clinical cohorts.
Design and optimisation of multiplex immunoassays and monoclonal antibody-based measurement platforms for parallel protein quantification.
Computational analysis, statistical modelling and machine-learning to process high-throughput proteomic/genomic data and develop diagnostic algorithms.
Support for multi-site clinical sample collection, study execution and performance assessment against clinical benchmarks.
Formation and leadership of multi-partner consortia and management of externally funded projects (EU, national agency, philanthropic).
Expertise Areas
- Biomarker discovery and commercialization
- Host immune-protein based diagnostics
- Proteomics and multiplex immunoassays
- Clinical validation of diagnostics
Key Technologies
- High-throughput immunoassays
- Multiplex protein assays
- Monoclonal antibody biochips
- Machine learning for pattern recognition
News & Updates
A grant from the Bill & Melinda Gates Foundation to develop blood tests for monitoring TB treatment response.
Participation in industry event to promote TB diagnostic technology.
Coverage of clinical validation of blood-based TB diagnostic.
Approval of first patent for biomarkers in TB diagnosis, with a second patent filed.
A grant from the Bill & Melinda Gates Foundation to develop blood tests for monitoring TB treatment response.
Participation in industry event to promote TB diagnostic technology.
Coverage of clinical validation of blood-based TB diagnostic.
Approval of first patent for biomarkers in TB diagnosis, with a second patent filed.